Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Discovery and characterization of the cytokine receptor-cytokine-decoy receptor triad formed by receptor activator of nuclear factor kappa-B ligand (RANKL)–receptor activator of NF-κB (RANK)–osteoprotegerin (OPG) have led not only to immense advances in understanding the biology of bone homeostasis, but have also crystalized appreciation of the critical regulatory relationship that exists between bone and immunity, resulting in the emergence of the burgeoning field of osteoimmunology. RANKL–RANK–OPG are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies, and share signaling characteristics common to many members of each. Developmentally regulated and cell-type specific expression patterns of each of these factors have revealed key regulatory functions for RANKL–RANK–OPG in bone homeostasis, organogenesis, immune tolerance, and cancer. Successful efforts at designing and developing therapeutic agents targeting RANKL–RANK–OPG have been undertaken for osteoporosis, and additional efforts are underway for other conditions. In this review, we will summarize the basic biology of the RANKL–RANK–OPG system, relate its cell-type specific functions to system-wide mechanisms of development and homeostasis, and highlight emerging areas of interest for this cytokine group.

[1]  Frédéric Blanchard,et al.  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK , 2006 .

[2]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[3]  Qiongqing Wang,et al.  ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. , 2009, Genes & development.

[4]  T. Taniguchi,et al.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.

[5]  Shuying Yang,et al.  RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation. , 2007, Genes & development.

[6]  J. Penninger,et al.  The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis , 2005, Nature Medicine.

[7]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[8]  D. Lo,et al.  Jagged1 and Notch1 help edit M cell patterning in Peyer's patch follicle epithelium. , 2012, Developmental and comparative immunology.

[9]  R. Faccio,et al.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.

[10]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[11]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[12]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[13]  M. Walsh,et al.  Biology of the TRANCE axis. , 2003, Cytokine & growth factor reviews.

[14]  B. Aggarwal,et al.  Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.

[15]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[16]  M. Habal,et al.  Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism , 2001, Nature Genetics.

[17]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[18]  N. Sakamoto,et al.  RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4+CD25+ Regulatory T Cells in Chronic Colitis1 , 2009, The Journal of Immunology.

[19]  T. Kodama,et al.  Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals , 2008, Cell.

[20]  A. Kudo,et al.  Self‐Assembled RANK Induces Osteoclastogenesis Ligand‐Independently , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[22]  Yasuhiro Kobayashi,et al.  Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. , 2011, Frontiers in bioscience.

[23]  I. Holen,et al.  Targeting RANKL in metastasis , 2014, BoneKEy reports.

[24]  L. Bonewald,et al.  MLO‐Y4 Osteocyte‐Like Cells Support Osteoclast Formation and Activation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  E. Wagner,et al.  Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation , 2000, Nature Genetics.

[26]  Kosaku Kurata,et al.  Evidence for osteocyte regulation of bone homeostasis through RANKL expression , 2011, Nature Medicine.

[27]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[28]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[29]  F. Kronenberg,et al.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus , 2013, Nature Medicine.

[30]  Zhijian J. Chen,et al.  Ubiquitination in signaling to and activation of IKK , 2012, Immunological reviews.

[31]  Hiroshi Takayanagi,et al.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis , 2013, Nature Medicine.

[32]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[33]  G. Rodan,et al.  Pathogenesis of osteoporosis. , 2003, Endocrinology and metabolism clinics of North America.

[34]  Wassim Raffoul,et al.  Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast , 2013, Science Translational Medicine.

[35]  M. Naramura,et al.  A Positive Regulatory Role for Cbl Family Proteins in Tumor Necrosis Factor-related Activation-induced Cytokine (TRANCE) and CD40L-mediated Akt Activation* , 2001, The Journal of Biological Chemistry.

[36]  R. Schüle,et al.  FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. , 2005, The Journal of clinical investigation.

[37]  J. Penninger,et al.  Receptor activator of NF-κB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit , 2011, Proceedings of the National Academy of Sciences.

[38]  A. Kudo,et al.  TRAF2 Is Essential for TNF‐α‐Induced Osteoclastogenesis , 2004 .

[39]  H. Blair,et al.  Tumor Necrosis Factor Family Receptors Regulating Bone Turnover , 2007, Annals of the New York Academy of Sciences.

[40]  P. Kostenuik,et al.  Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.

[41]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[42]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Kiyono,et al.  RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium1 , 2009, The Journal of Immunology.

[44]  H. Takayanagi New developments in osteoimmunology , 2012, Nature Reviews Rheumatology.

[45]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[46]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[47]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[48]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[49]  B. Olsen,et al.  Increased Myeloid Cell Responses to M-CSF and RANKL Cause Bone Loss and Inflammation in SH3BP2 “Cherubism” Mice , 2007, Cell.

[50]  E. Wagner,et al.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.

[51]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[52]  T. Akiyama,et al.  Regulations of Gene Expression in Medullary Thymic Epithelial Cells Required for Preventing the Onset of Autoimmune Diseases , 2013, Front. Immunol..

[53]  W. Dougall,et al.  A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.

[54]  E. Schmidt,et al.  IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. , 2001, Cell.

[55]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[56]  B. Kwon,et al.  TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  A. Leonardi,et al.  Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.

[58]  A. Kudo,et al.  TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[60]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[61]  Hiroshi Takayanagi,et al.  Mechanistic insight into osteoclast differentiation in osteoimmunology , 2005, Journal of Molecular Medicine.

[62]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[63]  Mark S. Anderson,et al.  Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance , 2014, The Journal of Experimental Medicine.

[64]  R. Steinman,et al.  TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. , 1999, Journal of immunology.

[65]  H. Kitaura,et al.  Immunological Reaction in TNF-α-Mediated Osteoclast Formation and Bone Resorption In Vitro and In Vivo , 2013, Clinical & developmental immunology.

[66]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[67]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[68]  B. Aggarwal,et al.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.

[69]  S. Akira,et al.  TRAF Family Member-associated NF-κB Activator (TANK) Is a Negative Regulator of Osteoclastogenesis and Bone Formation* , 2012, The Journal of Biological Chemistry.

[70]  E. Wagner,et al.  NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.

[71]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[72]  T. Takeya,et al.  Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.

[73]  H. Ryoo,et al.  Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross‐talking with RANK signaling , 2008, Journal of cellular physiology.

[74]  Jinhu Xiong,et al.  Matrix-embedded cells control osteoclast formation , 2011, Nature Medicine.

[75]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[76]  C. O’Brien,et al.  Osteocyte RANKL: New insights into the control of bone remodeling , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  C. Mueller,et al.  Emerging Functions of RANKL in Lymphoid Tissues , 2012, Front. Immun..

[78]  L. Hofbauer,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[79]  N A Mabbott,et al.  Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium , 2013, Mucosal Immunology.

[80]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[81]  Y. Kadono,et al.  Strength of TRAF6 signalling determines osteoclastogenesis , 2005, EMBO reports.

[82]  L. Xing,et al.  NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. , 2009, The Journal of clinical investigation.

[83]  Natalie A. Roberts,et al.  Rank Signaling Links the Development of Invariant γδ T Cell Progenitors and Aire+ Medullary Epithelium , 2012, Immunity.

[84]  I. Williams,et al.  Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine. , 2011, The American journal of pathology.

[85]  M. Karin,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.

[86]  Shao-Cong Sun,et al.  Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. , 2008, The Journal of clinical investigation.

[87]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[88]  K. Hirokawa,et al.  Multimerization of the Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis* , 2003, Journal of Biological Chemistry.

[89]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[90]  Hyunsook Kim,et al.  Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation. , 2013, Cell metabolism.

[91]  T. Izumi [Management of bone disease in multiple myeloma]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[92]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[93]  M. Kumegawa,et al.  Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. , 1998, Biochemical and biophysical research communications.

[94]  W. de Lau,et al.  Peyer's Patch M Cells Derived from Lgr5+ Stem Cells Require SpiB and Are Induced by RankL in Cultured “Miniguts” , 2012, Molecular and Cellular Biology.

[95]  L. Xing,et al.  Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. , 2014, The Journal of clinical investigation.

[96]  T. Kodama,et al.  Osteoprotection by semaphorin 3A , 2012, Nature.

[97]  N. Sakurai,et al.  Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.

[98]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[99]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[100]  I. Ishikawa,et al.  LPS‐stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin , 2002, Clinical and experimental immunology.

[101]  T. Nishihara,et al.  p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. , 2002, Endocrinology.

[102]  H. Takayanagi,et al.  The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. , 2008, Immunity.

[103]  Sakae Tanaka,et al.  Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[104]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[105]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[106]  Steffen Jung,et al.  Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance , 2000, The Journal of experimental medicine.

[107]  G. Mundy Osteoporosis and inflammation. , 2007, Nutrition reviews.

[108]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[109]  R. Steinman,et al.  The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.

[110]  T. Komori,et al.  Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.

[111]  C. O’Brien,et al.  Receptor Activator of Nuclear Factor κB Ligand (RANKL) Protein Expression by B Lymphocytes Contributes to Ovariectomy-induced Bone Loss* , 2012, The Journal of Biological Chemistry.

[112]  S. Ricard-Blum,et al.  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. , 2006, Biochemical and biophysical research communications.

[113]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[114]  Y. Kong,et al.  Survival and Differentiation of Mammary Epithelial Cells in Mammary Gland Development Require Nuclear Retention of Id2 Due to RANK Signaling , 2011, Molecular and Cellular Biology.

[115]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[116]  J. Branco,et al.  Rank/Rankl/opg: literature review. , 2011, Acta reumatologica portuguesa.

[117]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[118]  M. Whyte,et al.  Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[119]  T. Kaisho,et al.  The Ets Transcription Factor Spi-B Is Essential for the Differentiation of Intestinal Microfold (M) Cells , 2012, Nature Immunology.

[120]  M. Heymann,et al.  Osteoprotegerin: multiple partners for multiple functions. , 2013, Cytokine & growth factor reviews.

[121]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[122]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[123]  J. Caamaño,et al.  Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. , 1997, Nature medicine.

[124]  R. Flavell,et al.  Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. , 2002, Immunity.

[125]  J. Caamaño,et al.  The thymic medulla is required for Foxp3+ regulatory but not conventional CD4+ thymocyte development , 2013, The Journal of experimental medicine.

[126]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[127]  J. Penninger,et al.  Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells , 2006, Nature Medicine.

[128]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[129]  R. Steinman,et al.  Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in Vivo , 2000, The Journal of experimental medicine.

[130]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[131]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[132]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[133]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[134]  J. Penninger,et al.  Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2 , 2006, Molecular and Cellular Biology.

[135]  D. Lacey,et al.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.

[136]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[137]  L. Hood,et al.  OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.

[138]  G. Bishop,et al.  TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development , 2013, Proceedings of the National Academy of Sciences.

[139]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[140]  N. Nagata,et al.  Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .

[141]  J. Penninger,et al.  RANKL/RANK - from bone physiology to breast cancer. , 2014, Cytokine & growth factor reviews.

[142]  B. Boyce Advances in the Regulation of Osteoclasts and Osteoclast Functions , 2013, Journal of dental research.

[143]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .

[144]  W. Zou,et al.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. , 2008, Molecular cell.

[145]  Masaru Ishii,et al.  Dynamic visualization of RANKL and Th17-mediated osteoclast function. , 2013, The Journal of clinical investigation.